

REMARKS

The specification has been amended to include a cross reference related applications. No new matter is added by this amendment.

The claims presented in the parent PCT application have been re-written to conform with U.S. practice and to remove multiple dependences. To facilitate this process, claims 1-16 have been canceled and replaced by new claims 17-52.

The claims have been amended to replace each instance of the abbreviation “alk(en/yn)yl” in all its forms to with the three particular chains represented thereby, viz., “alkyl, alkenyl, and alkynyl.-- Support for these amendments is found in the specification at page 4, lines 8-9 and 20-25 and page 5, lines 1-2.

In new claim 38, the compound “4-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenyl]-piperidine” that is found in at page 9, line 12 of the present amendment replaces the compound “4-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenyl]-” that was previously recited in claim 12. *See* specification at page 83, line 25. Support for this replacement is found in the specification at page 62, line 23 (Example 3a1).

More generally, support for the new claims is found in the originally filed claims as follows:

Claims 17: Supported by original claim 1.

Claims 18 and 19: Supported by original claim 2.

Claims 20 and 21: Supported by original claim 3.

Claims 22 and 24: Supported by original claim 4.

Claims 25 and 26: Supported by original claim 5.

Claims 27 and 28: Supported by original claim 6.

Claims 29 and 30: Supported by original claim 7.

Claims 31 and 32: Supported by original claim 8.

Claims 33 and 34: Supported by original claim 9.

Claims 35 and 36: Supported by original claim 10.

Claim 37: Supported by original claim 11.

Claim 38: Supported by original claim 12.

Claims 39 and 46: Supported by original claim 13.


Claims 40-45 and 47-52: Supported by original claim 15.

All amendments are supported by the application as filed. By this Preliminary Amendment, no new matter has been introduced into the application.

This application is believed to be in condition for allowance. A prompt and favorable action on the merits of the application is earnestly solicited.

Dated: November 29, 2005

Respectfully submitted,

By 

Mitchell Bernstein, Ph.D.

Registration No.: 46,550

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant